Skip to main content

Table 3 Details of the replicated loci both from published studies, replication cohort and strongest signal in the region

From: Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients

Reference Locus Published SNP Strongest signal in the locus (current study) Position (hg38) Risk allele Published studies Replication
Effect size (OR/HR) P-value Medication Association OR P-value Imputation Info
Diouf 14q21.1 rs8014839   39,374,915 G 3.63 5.1 × 10−6 Vincristine 1.55 0.0006 0.99
    rs8014839a 39,374,915 G   NA NA NA
Diouf 4q28.1 rs4618330   126,757,231 A 0.47 6.4 × 10− 6 Vincristine 0.7 0.004 0.98
    rs28742896 c 127,678,685 A   0.6 0.0001 0.99
Baldwin 3q27.3 rs1903216   187,911,715 A 1.59 5.6 × 10−6 Paclitaxel 1.4 0.006 1
    rs2611620 c 187,826,512 A   1.69 5.6 × 10−5 0.98
Diouf 3p14.2 rs35558909   60,933,303 G 3.17 4.3 × 10−7 Vincristine 1.36 0.01 0.98
    rs2121845 a 60,922,227 A   1.76 0.01 1
Diouf 3p21.1 rs4687753   53,861,434 A 4.49 6.2 × 10−6 Vincristine 1.32 0.03 0.99
    rs9840079b 53,858,614 T   1.39 0.007 0.99
Diouf 8q24.12 rs7817522   120,028,312 T 4.21 3.1 × 10−6 Vincristine 1.3 0.03 0.99
    rs17822044a 119,997,585 G   1.35 0.02 1
Schneider 15q21.3 rs2062640   54,737,776 G 2.01 7.9 × 10− 6 Paclitaxel 1.42 0.04 1
    rs2695677 c 54,799,953 C   1.96 0.0003 0.98
Diouf 2q33.3 rs11694118   208,077,000 A 0.18 8.8 × 10−6 Vincristine 0.75 0.04 0.96
    rs17538082a 208,060,995 T   0.73 0.03 1
Diouf 5q23.2 rs10070183   124,521,298 C 0.43 2.8 × 10− 6 Vincristine 0.77 0.04 0.95
    rs10478625b 124,527,954 T   0.71 0.009 1
  1. Chr Chromosome, SNP Single nucleotide polymorphism, OR Odds ratio, HR Hazard ratio, NA: not applicable
  2. ar2 ≥ 0.8, b r2 ≥ 0.6, c r2 ≥ 0.4 (r2: The linkage disequilibrium metrics between the SNPs), Imputation Info: the score ranging between 0 and 1 which is the indicator of the certainty of imputation for each SNP